1.Theelen W, Baas P. Pembrolizumab monotherapy for PD-L1>/=50% non-small cell lung cancer, undisputed first choice?Ann Transl Med 2019;7:S140.
2. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. Appl Immunohistochem Mol Morphol 2016;24:392-7.
3. Sánchez-Magraner L, Miles J, Baker CL, et al. High PD-1/PD-L1 checkpoint interaction infers tumor selection and therapeutic sensitivity to anti-PD-1/PD-L1 treatment [published online ahead of print, 2020 Aug 27]. Cancer Res. 2020;canres.1117.2020.
4. ShridarGanesan,Janice Mehner. Biomarkersfor Response to Immune Checkpoint Blockade [J]. Annual Review of CancerBiology, 2019.
5. Yu Chen, Yi Li, Yanfang Guan, etal. Prevalence of PRKDC mutations and association with response to immunecheckpoint inhibitors in solid tumors [J]. Molecular Oncology,2020.
6.Kim ST, et al.Comprehensive molecular characterization of clinical responses to PD-1inhibition in metastatic gastric cancer [J]. Nature Medicine, 2018
7. Scott V. Bratman. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab [J].Journal of Clinical Oncology, 2020
8.Kim S T, Cristescu R, Bass A J, et al.Comprehensive molecular characterization of clinical responses to PD-1inhibition in metastatic gastric cancer[J]. Nature Medicine, 2018.
9.Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
10.Study identifies characteristics of infused CAR T cells in patients with large B-cell lymphoma
Yu Chen, Yi Li, Yanfang Guan, etal. Prevalence of PRKDC mutations and association with response to immunecheckpoint inhibitors in solid tumors [J]. Molecular Oncology,2020.